You are here

  • Home
  • Archive
  • Volume 47, Issue 4
  • COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

Article info

Article menu
Download PDFPDF
Small intestinal disease
COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

Authors

  • G Sigthorsson aDepartment of Medicine, Guy's, King's, St Thomas' Medical School, London, UK, bClinical Research Department, Merck Research Laboratories, West Point, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • R Crane aDepartment of Medicine, Guy's, King's, St Thomas' Medical School, London, UK, bClinical Research Department, Merck Research Laboratories, West Point, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • T Simon aDepartment of Medicine, Guy's, King's, St Thomas' Medical School, London, UK, bClinical Research Department, Merck Research Laboratories, West Point, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • M Hoover aDepartment of Medicine, Guy's, King's, St Thomas' Medical School, London, UK, bClinical Research Department, Merck Research Laboratories, West Point, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • H Quan aDepartment of Medicine, Guy's, King's, St Thomas' Medical School, London, UK, bClinical Research Department, Merck Research Laboratories, West Point, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • J Bolognese aDepartment of Medicine, Guy's, King's, St Thomas' Medical School, London, UK, bClinical Research Department, Merck Research Laboratories, West Point, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • I Bjarnason aDepartment of Medicine, Guy's, King's, St Thomas' Medical School, London, UK, bClinical Research Department, Merck Research Laboratories, West Point, Pennsylvania, USA PubMed articlesGoogle scholar articles
  1. Professor I Bjarnason, Department of Medicine, Guy's, King's, St Thomas' Medical School, Bessemer Road, London SE5 9PJ, UK. Email: ingvar.bjarnason{at}kcl.ac.uk
View Full Text

Citation

Sigthorsson G, Crane R, Simon T, et al
COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin
Gut 2000;47:527-532.

Publication history

  • Accepted April 4, 2000
  • First published October 1, 2000.
Online issue publication 
January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

British Society of Gastroenterology